相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix (TM)] - A review of its use as an active immunization against influenza A subtype H5N1 virus
Natalie J. Carter et al.
BIODRUGS (2008)
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
Anja Seubert et al.
JOURNAL OF IMMUNOLOGY (2008)
An adjuvanted, low-dose, pandemic influenza a (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
Karin Levie et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults
David I. Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant
Nega Ali Goji et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
Isabel Leroux-Roels et al.
PLOS ONE (2008)
Molecular and cellular signatures of human vaccine adjuvants
F. Mosca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
Andreas Wack et al.
VACCINE (2008)
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial
Hans C. Rumke et al.
VACCINE (2008)
Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
Filippo Ansaldi et al.
VACCINE (2008)
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling
Felix Geeraedts et al.
PLOS PATHOGENS (2008)
Vaccination of Macaques with adjuvanted formalin-inactivated influenza a virus (H5N1) vaccines: Protection against H5N1 challenge without disease enhancement
Caroline Ruat et al.
JOURNAL OF VIROLOGY (2008)
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Derek T. O'Hagan
EXPERT REVIEW OF VACCINES (2007)
Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases
V. Baldo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Ab and T cell epitopes of influenza A virus, knowledge and opportunities
Huynh-Hoa Bui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene
Giuseppe Del Giudice et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
T cell responses are better correlates of vaccine protection in the elderly
JE McElhaney et al.
JOURNAL OF IMMUNOLOGY (2006)
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
G Del Giudice et al.
VACCINE (2006)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Translating innate immunity into immunological memory: Implications for vaccine development
B Pulendran et al.
CELL (2006)
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy
I Stephenson et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Age-related impaired type 1 T cell responses to influenza: Reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly
YP Deng et al.
JOURNAL OF IMMUNOLOGY (2004)
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
I Stephenson et al.
VACCINE (2003)
Effect of priming on subsequent response to inactivated influenza vaccine
CW Potter et al.
VACCINE (2003)
Developing vaccines against pandemic influenza
JM Wood
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2001)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
KG Nicholson et al.
LANCET (2001)
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans
TG Evans et al.
VACCINE (2001)
Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects
R Gasparini et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2001)
Effectiveness and cost-benefit of influenza vaccination of healthy working adults - A randomized controlled trial
CB Bridges et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
The effect of age on the B-Cell repertoire
ME Weksler et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2000)
分享论文
